Skip to main content

Table 1 Summary of characteristics, study outcomes and details of addressing and reporting adherence in the randomized controlled trials included in the study

From: Medication adherence in randomized controlled trials evaluating cardiovascular or mortality outcomes in dialysis patients: A systematic review

Reference Year of publication Population Total N (Intervention/Control) Therapy (Intervention/Control) Trial outcome Reported Adherence Addressing Adherence Drug discontinuation: Intervention/Control arms
Baigent et al. [9] 2011 HD & PDa 3023 (1533/1490)b Simvastain + Ezetimibe/Placebo Negativeb,c 65%b in the Inter-vention group Run-in phase to identify non-compliers 33%/36%e,f
Block et al. [26] 2007 HD 127 (60/67) Sevalamer/Ca based binders Positive Not reported Specified as not checked Not reported
Chertow et al. [17] 2012 HD 3883 (1948/1935) Cinacalcet/Placebo Negative Not reported TNA reported as cause of therapy discontinuation. Reports lag censored analysis after therapy cessation 67%/71%f,g,h
Cice et al. [24] 2010 HD 332 (165/167) Add-on Telmisartan (to ACEI)/Placebo Positive Not reported Not addressed 16/11%f,i
Di Iorio et al. [27] 2013 HD 466 (232/234) Sevalamer/Ca based binders Positive Not reported Not addressed 14%/15%i
Dixon et al. [28] 2009 HD 649 (321/328) Dipyridamole + Aspirin/Placebo Negatived 83%/83% Assessed by pill count & reported 30%/26%f,i
Fellstrom et al. [10] 2009 HD 2773 (1389/1384) Rosuvastatin/Placebo Negative 92%/86% Assessed by pill count & reported 73%/74%f,g,h,i,j
Iseki et al. [25] 2013 HD 469 (235/234) Olmesartan/Usual care but No ARB or ACEI Negative Not reported Not addressed 49% in interventionf,h
Jamison et al. [19] 2007 HD & PDa 751 (372/379)b Folic acid + B6 + B12/Placebo Negative 85%/87% Assessed by pill count & reported 27%/26%i
Lok et al. [32] 2012 HD 196 (99/97) Fish oil/Placebo Positived Not reported Blood tests supporting drug effect reported, but not at patient level 16%/16%i,j
Matsumoto et al. [30] 2014 HD 309 (157/152) Spironolactone/Usual care Positive Not reported Non-adherent patients excluded from participation 29%/16%f
Nishimura et al. [29] 2009 HD 129 (64 + 65) Nicorandil/Usual care but no Nicorandil Positive Not reported Not addressed 0%/0%
Righetti et al. [31] 2006 HD 88 (37/51) Folic acid/Usual care Positive Not reported Reported as measured, but not reported 72% e,f,h,I,j
Stegmayr et al. [11] 2005 HD & PDa 110 (53/57)b Atorvastatin/Placebo Negative Not reported Non-adherent patients excluded from participation 33%/6%f
Suki et al. [15] 2007 HD 2103 (1053/1050) Sevalamer/Ca based binders Negative Not reported TNA reported as cause of therapy discontinuation 48%/51%f,g,h
Suzuki et al. [22] 2008 HD 366 (183/183) Any ARB/Usual care but no ARB Positive Not reported Not addressed 2%/2%f
Svensson et al. [14] 2006 HD 206 (103/103) Omacor (3-PUFA)/Placebo Negative Not reported Non-adherent patients excluded, Blood tests supporting drug effect reported, but patient level adherence not reported 27%/22%f,g
Takahashi et al. [21] 2006 HD 80 (43/37) Candesartan/Usual care Positive Not reported Non-adherent patients excluded from participation 0%/0%
Tepel et al. [23] 2008 HD 251 (123/128) Amlodipine/Placebo Negative Not reported TNA reported as cause of therapy discontinuation 63%/65%f,g,h,i,j
Wanner et al. [8] 2005 HD 1255 (619/636) Atorvastatin/Placebo Negative 80%/82% Assessed by pill count & reported 23%/24%f
Wilson et al. [16] 2009 HD 1354 (680/674) Lanthanum/Usual care Negative Not reported Not addressed 72%/53%f,g,h,i,j
Zannad et al. [20] 2006 HD 397 (196/201) Fosinopril/Placebo Negative Not reported Not addressed 4%/5%h
  1. aThe trial also included patient not on dialysis. bThe data given pertains to dialysis patients only. cThe trial was positive for the overall cohort. dCardiovascular or mortality outcome was a secondary outcome. eThe result is for the overall cohort. fIncludes adverse events as a cause of drug discontinuation. gIncludes non-adherence as a cause of drug discontinuation. hIncludes kidney transplantation as a cause of drug discontinuation. iIncludes drop-out or loss to follow up as a cause of drug discontinuation. jIncludes death as a cause of drug discontinuation. HD Haemodialysis. PD Peritoneal dialysis. TNA Treatment non-adherence